The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis

  title={The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis},
  author={Simon B. Goldberg and Brian T. Pace and Christopher R Nicholas and Charles L. Raison and Paul Hutson},
  journal={Psychiatry Research},

Tables from this paper

Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis
The effects of psilocybin, ayahuasca, and lysergic acid diethylamide (LSD) on psychological outcomes in the post-acute period are quantified and test moderators of these effects are evaluated; adverse effects and risk of bias are evaluated.
Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis
Psilocybin, ayahuasca and LSD all appear to be effective and relatively safe agents capable of producing rapid and sustained improvements in anxiety and depression, and may show a greater efficacy when given to patients over multiple sessions as compared to the more common single session used in many of the existing trials.
Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases—A Systematic Review and Meta-Analysis of Clinical Trials
The obtained results are promising and emphasize the importance of psilocybin translational research in the management of symptoms of depression and anxiety, since the compound may be effective in reducing symptoms of Depression and anxiety in conditions that are either resistant to conventional pharmacotherapy or for which pharmacologic treatment is not yet approved.
Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A Systematic Review and Multivariate Meta-Analysis
It is demonstrated that single- or two-dose psilocybin administration has rapid and sustained antidepressant effects for up to 6 months, with favorable cardiovascular safety and acceptability.
A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders
Methylenedioxymethamphetamine and psilocybin may show promise in highly selected populations when administered in closely supervised settings and with intensive support, and both agents were well tolerated in supervised trials.
The therapeutic potential of microdosing psychedelics in depression
  • K. Kuypers
  • Psychology
    Therapeutic advances in psychopharmacology
  • 2020
While it is yet unclear whether psychedelic microdosing is of therapeutic value for depression, the aforementioned effects on selective processes suggest that low doses of psychedelics could play a role in depression by inducing some kind of cognitive flexibility, which might lead to decreased rumination.
Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review
Psilocybin-containing mushrooms have been consumed by various cultures in many different parts of the world for thousands of years. Psilocybin, a classic psychedelic, contains unique psychoactive
The Use of Psilocybin in the Treatment of Psychiatric Disorders with Attention to Relative Safety Profile: A Systematic Review.
There has been a reemergence of research into the use of substances such as LSD, MDMA, and psilocybin for the treatment of psychiatric disorders. This increase in consideration toward the medicinal
Future directions for clinical psilocybin research: The relaxed symptom network.
Recent clinical trials have demonstrated that psilocybin may have strong antidepressant effects, and may be effective in the treatment of depressive disorders when embedded in a psychotherapeutic
Rediscovering Psilocybin as an Antidepressive Treatment Strategy
An overview of the current state of research on the potential mechanisms of psilocybin, its antidepressant potential, and the associated risks and adverse effects is provided to provide an update on a controversial topic discussed in psychopharmacology.


Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
High-dose psilocybin produced large decreases in clinician- and self-rated measures of depressed mood and anxiety, along with increases in quality of life, life meaning, and optimism, and decreases in death anxiety.
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
This study established the feasibility and safety of administering moderate doses of psilocybin to patients with advanced-stage cancer and anxiety and revealed a positive trend toward improved mood and anxiety.
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
Psilocybin was associated with enduring anxiolytic and anti-depressant effects in patients with cancer-related psychological distress, sustained benefits in existential distress and quality of life, as well as improved attitudes towards death.
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
A single-group proof-of-concept study to quantify acute effects of psilocybin in alcohol-dependent participants and to provide preliminary outcome and safety data, providing a strong rationale for controlled trials with larger samples to investigate efficacy and mechanisms.
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Although limited conclusions can be drawn about treatment efficacy from open-label trials, tolerability was good, effect sizes large and symptom improvements appeared rapidly after just two psilocybin treatment sessions and remained significant 6 months post-treatment in a treatment-resistant cohort.
Long-term follow-up of psilocybin-facilitated smoking cessation
The results suggest that in the context of a structured treatment program, psilocybin holds considerable promise in promoting long-term smoking abstinence, adding to recent and historical evidence suggesting high success rates when using classic psychedelics in the treatment of addiction.
A multidimensional meta-analysis of treatments for depression, panic, and generalized anxiety disorder: an empirical examination of the status of empirically supported therapies.
A meta-analysis of high-quality studies published from 1990-1998 on the efficacy of manualized psychotherapies for depression, panic disorder, and generalized anxiety disorder suggests that a substantial proportion of patients with panic improve and remain improved.
Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews
Results are promising, several studies were open label, and only few were RCTs, and most had small sample sizes and a short duration, but long-term studies are lacking.